Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma
- 1 March 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 19 (3), 895-905
- https://doi.org/10.1158/1535-7163.mct-19-0290
Abstract
Receptor tyrosine kinase AXL is found upregulated in various types of cancer, including melanoma, and correlates with an aggressive cancer phenotype, inducing cell proliferation and epithelial-to-mesenchymal transition. Additionally, AXL has recently been linked to chemotherapy resistance and inhibition of AXL is found to increase DNA damage and reduce expression of DNA repair proteins. In light of this, we aimed to investigate if targeting AXL together with DNA damage response proteins would be therapeutically beneficial. Using melanoma cell lines, we observed that combined reduction of AXL and CHK1/CHK2 signaling decreased proliferation, deregulated cell cycle progression, increased apoptosis and reduced expression of DNA damage response proteins. Enhanced therapeutic effect of combined- as compared to mono-treatments was further observed in a patient-derived xenograft model and, of particular interest, when applying a three-dimensional ex vivo spheroid drug-sensitivity assay on tumor cells harvested directly from 27 patients with melanoma lymph node metastases. Together, these results indicate that targeting AXL together with the DNA damage response pathway could be a promising treatment strategy in melanoma and that further investigations in patient groups lacking treatment alternatives should be pursued.Other Versions
Funding Information
- Ministry of Health and Care Services | Helse Sør-Øst RHF
This publication has 55 references indexed in Scilit:
- Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiationCell Death & Disease, 2012
- High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted TherapyPLOS ONE, 2012
- The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic targetOncogene, 2012
- Axl-dependent signalling: a clinical updateClinical Science, 2011
- Human Cutaneous Melanomas Lacking MITF and Melanocyte Differentiation Antigens Express a Functional Axl Receptor KinaseJournal of Investigative Dermatology, 2011
- Liposome-based DNA carriers may induce cellular stress response and change gene expression pattern in transfected cellsBMC Molecular Biology, 2011
- AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian CancerCancer Research, 2010
- Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cellsPigment Cell & Melanoma Research, 2010
- Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survivalProceedings of the National Academy of Sciences of the United States of America, 2009
- Protein kinases in normal and transformed melanocytesMelanoma Research, 1994